The Department of Pharmaceuticals announced a New Discovery Track under the PRIP Scheme: up to Rs 50 crore per company, project or portfolio for start-ups and MSMEs doing new-drug discovery, with at least 25% of project cost co-funded by bona fide institutional investors.
Under PRIP's first call, 41 projects have been approved for about Rs 1,600 crore; they are expected to draw another Rs 3,020 crore of private investment, about Rs 4,620 crore in all.
Of the 41, 12 are early-stage and 29 later-stage; 19 come from start-ups and MSMEs and 22 from large companies; 27 are New Medicines, five Complex Generics and Biosimilars, nine Novel Medical Devices.
The PRIP portal is open for the second call on three tracks: New Discovery, Early Stage (up to Rs 5 crore) and Later Stage (up to Rs 100 crore).
| Aspect | New Discovery | Early Stage | Later Stage |
|---|---|---|---|
| Who can apply | Start-ups and MSMEs (NCE/NBE projects) | Start-ups and MSMEs | Industry, start-ups and MSMEs |
| Entry level | TRL 1, 2 or 3 | TRL 1, 2 or 3 | TRL 4, 5 or 6 |
| Supported up to | Not beyond TRL 6 | Not beyond TRL 5 | Higher TRLs |
| Maximum assistance | Rs 50 crore per company, project or portfolio | Rs 5 crore per project | Rs 100 crore per project |
| Co-funding | At least 25% of project cost from bona fide institutional investors | None up to Rs 1 crore of cost; half of the cost above Rs 1 crore | Assistance capped at 35% of approved cost; applicant funds the rest |
A nine-step scale, devised at NASA in the 1970s, for how mature a technology is. TRL 1 means basic principles observed; TRL 9 means a system proven in real operation. PRIP's discovery funding starts at TRL 1-3.
Reward production of high-value drugs.
Key: Rs 15,000 crore; FY 2020-21 to 2028-29; 55 applicants selected. Rewards output; PRIP funds research.
Cut import dependence in APIs and high-end devices.
Key: Bulk drugs: Rs 6,940 crore, 41 products. Medical devices: Rs 3,420 crore. Both under the Department of Pharmaceuticals.
Make India a hub for biologics and biosimilars.
Key: Union Budget 2026-27; Rs 10,000 crore over five years; three new NIPERs, seven upgraded; over 1,000 accredited clinical trial sites.
Long-term, low-cost finance for private R&D.
Key: Rs 1 lakh crore; Cabinet approval 1 July 2025; Department of Science and Technology nodal; routed through a Special Purpose Fund in ANRF.
Created 1 July 2008 in the Ministry of Chemicals and Fertilizers; runs PRIP, the PLI schemes and the NIPERs.
Institutes of National Importance under the NIPER Act, 1998. Seven: Mohali (the first), Ahmedabad, Guwahati, Hajipur, Hyderabad, Kolkata, Raebareli.
Apex research-funding body under the ANRF Act, 2023 (in force 5 February 2024); replaced the Science and Engineering Research Board; Rs 50,000 crore estimated for 2023-28; under the Department of Science and Technology.
GS Paper 3 > Science and Technology > Indigenisation of Technology; GS Paper 2 > Health
General Awareness > Government Schemes > Pharmaceuticals
New Chemical Entity / New Biological Entity: a drug molecule not previously approved, chemical or biological in origin.
A biological medicine highly similar to an already approved reference biologic.
Money put into ventures with a high chance of failure, as in early drug discovery; the Discovery Track pairs public grants with investor money.